脂蛋白a与支架内再狭窄相关性的研究进展  

The Correlation Between Lipoprotein (a) and In-Stent Restenosis

作　　者：王振宇 张飞飞[2] 党懿[2] WANG Zhenyu;ZHANG Feifei;DANG Yi(Hebei Medical University Graduate School,Shijiazhuang 050017,Hebei,China;Department of Cardiology,Hebei General Hospital,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北医科大学研究生院,河北石家庄050017 [2]河北省人民医院心内科,河北石家庄050051

出　　处：《心血管病学进展》2023年第9期786-789,共4页Advances in Cardiovascular Diseases

基　　金：2022年政府资助临床医学优秀人才项目(36100314)。

摘　　要：流行病学研究不断积累的证据表明,血浆中脂蛋白a [Lp(a)]水平的升高是冠状动脉粥样硬化性心脏病的独立危险因素。然而对于Lp(a)诱导支架内再狭窄的直接证据仍缺乏相关基础及临床研究,但目前研究表明Lp(a)可通过促进血栓形成、炎症反应及血管内膜增生影响支架内再狭窄的发生。现就Lp(a)的生物学特性、有关Lp(a)诱导支架内再狭窄的病理生理机制以及针对Lp(a)的相关治疗的研究进展进行综述。Accumulating evidence from epidemiological studies indicates that elevated plasma lipoprotein(a)[Lp(a)]level is independent risk factors for coronary atherosclerotic heart disease.However,there is still a lack of relevant basic and clinical research on the direct evidence of Lp(a) induced in-stent restenosis.Current studies have shown that Lp(a) can affect the occurrence of in-stent restenosis by promoting thrombosis,inflammatory response and intimal hyperplasia.This article reviews the biological characteristics of Lp(a),the pathophysiological mechanisms of Lp(a) induced in-stent restenosis,and the research progress in the treatment of Lp(a).

关 键 词：脂蛋白A 支架内再狭窄 冠状动脉粥样硬化性心脏病 

分 类 号：R541.4[医药卫生—心血管疾病]